Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers

Cephalalgia

Volumn 17, Issue 4, 1997, Pages 532-540

  Kunka, R L ^a   Hussey, E K ^a   Shaw, S ^a   Warner, P ^a   Aubert, B ^b   Richard, I ^b   Fowler, P A ^b   Pakes, G E ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Pharmacokinetics; Rectal absorption; Safety; Sumatriptan; Suppository; Tolerability

Indexed keywords

SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ELIMINATION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARESTHESIA; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; SUPPOSITORY; VERTIGO; VOLUNTEER;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; SEROTONIN AGONISTS; SUMATRIPTAN; SUPPOSITORIES;

EID: 0030976816     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1704532.x     Document Type: Article

References (19)

1. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
2. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
3. Sumatriptan Auto-injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an autoinjector device. Eur Neurol 1991;31:323-31
4. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991;338:782-3
5. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31:306-13
6. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138-44
7. Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991;12: 444-6
8. Data on file, Glaxo Wellcome Inc
9. Duquesnoy C, Mamet JP, Sumner DM, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Presented at the Third Conference of the European Headache Federation, Sardinia, Italy, June 5-8, 1996
10. Andrew PD, Birch HL, Phillpot DA. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Pharm Sci 1993;82:73-6
11. de Boer AG, Moolenaar F, de Leede LGJ, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982;7:285-311
12. Carstairs LS. Headache and gastric emptying rate. Proc R Soc Med 1958;5:790-1
13. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, Donn KH. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalgia 1991;11 Suppl 11:222-3
14. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543-8
15. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4
16. 1-like agonist GR43175 in healthy volunteers. Cephalalgia 1989;9 Suppl 9:57-62
17. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47:1253-7
18. Warner PE, Brouwer KLR, Hussey EK, Dukes GE, Heizer WD, Donn KH, et al. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm Res 1995; 12:138-43
19. Lacey LF, Fowler PA. The clinical pharmacology of sumatriptan [Abstract]. Cephalalgia 1993;13 Suppl 13:156